Structure-activity relationship of nerve-highlighting fluorophores

Nerve damage is a major morbidity associated with numerous surgical interventions. Yet, nerve visualization continues to challenge even the most experienced surgeons. A nerve-specific fluorescent contrast agent, especially one with near-infrared (NIR) absorption and emission, would be of immediate b...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 9; p. e73493
Main Authors Gibbs, Summer L, Xie, Yang, Goodwill, Haley L, Nasr, Khaled A, Ashitate, Yoshitomo, Madigan, Victoria J, Siclovan, Tiberiu M, Zavodszky, Maria, Tan Hehir, Cristina A, Frangioni, John V
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.09.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Nerve damage is a major morbidity associated with numerous surgical interventions. Yet, nerve visualization continues to challenge even the most experienced surgeons. A nerve-specific fluorescent contrast agent, especially one with near-infrared (NIR) absorption and emission, would be of immediate benefit to patients and surgeons. Currently, there are only three classes of small molecule organic fluorophores that penetrate the blood nerve barrier and bind to nerve tissue when administered systemically. Of these three classes, the distyrylbenzenes (DSBs) are particularly attractive for further study. Although not presently in the NIR range, DSB fluorophores highlight all nerve tissue in mice, rats, and pigs after intravenous administration. The purpose of the current study was to define the pharmacophore responsible for nerve-specific uptake and retention, which would enable future molecules to be optimized for NIR optical properties. Structural analogs of the DSB class of small molecules were synthesized using combinatorial solid phase synthesis and commercially available building blocks, which yielded more than 200 unique DSB fluorophores. The nerve-specific properties of all DSB analogs were quantified using an ex vivo nerve-specific fluorescence assay on pig and human sciatic nerve. Results were used to perform quantitative structure-activity relationship (QSAR) modeling and to define the nerve-specific pharmacophore. All DSB analogs with positive ex vivo fluorescence were tested for in vivo nerve specificity in mice to assess the effect of biodistribution and clearance on nerve fluorescence signal. Two new DSB fluorophores with the highest nerve to muscle ratio were tested in pigs to confirm scalability.
Bibliography:Competing Interests: The authors have declared the following interests: FLARETM technology is owned by Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. It has been licensed to the FLARETM Foundation, a non-profit organization focused on promoting the dissemination of medical imaging technology for research and clinical use. Dr. Frangioni is the founder and chairman of the FLARETM Foundation. The Beth Israel Deaconess Medical Center will receive royalties for sale of FLARETM Technology. Dr. Frangioni has elected to surrender post-market royalties to which he would otherwise be entitled as inventor, and has elected to donate pre-market proceeds to the FLARETM Foundation. Dr. Frangioni has started three for-profit companies, Curadel, Curadel ResVet Imaging, and Curadel Surgical Innovations, which may someday be non-exclusive sub-licensees of FLARETM technology. Co-authors Tiberiu M. Siclovan, Maria Zavodszky and Cristina A. Tan Hehir are employed by General Electric Company. Drs. Siclovan and Tan Hehir are inventors of patents and patent applications on technologies related to nerve imaging. These include US8169696B2 (Systems for intraoperative nerve imaging); US8114382B2 (Myelin detection using benzofuran derivatives); US20110142759A1 (Agents and methods for the imaging of myelin basic protein); US20100310457A1 and US20100310456A1 (imaging of myelin basic protein). There are no further products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: SLG KAN YA JVF. Performed the experiments: SLG YX HLG KAN YA VJM MZ. Analyzed the data: SLG YX HLG KAN YA VJM TMS MZ. Contributed reagents/materials/analysis tools: SLG YX HLG VJM TMS MZ CAT. Wrote the manuscript: SLG.
Current address: Department of Biomedical Engineering, Knight Cancer Institute and Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, Oregon, United States of America
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0073493